According to Aurinia Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$0.53. In 2022 the company made an earnings per share (EPS) of -$0.76 an increase over its 2021 EPS that were of -$1.41.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$0.53 | -30.26% |
2022 | -$0.76 | -46.1% |
2021 | -$1.41 | 63.95% |
2020 | -$0.86 | -33.85% |
2019 | -$1.30 | 73.33% |
2018 | -$0.75 | -34.78% |
2017 | -$1.15 | 74.24% |
2016 | -$0.66 | 13.79% |
2015 | -$0.58 | -15.94% |
2014 | -$0.69 | 61.51% |
2013 | -$0.43 | -83.03% |
2012 | -$2.52 | 621.77% |
2011 | -$0.35 | -75.81% |
2010 | -$1.44 | -53.29% |
2009 | -$3.09 | -59.15% |
2008 | -$7.56 | -50.57% |
2007 | -$15.29 | 16.07% |
2006 | -$13.17 | -28.86% |
2005 | -$18.52 | 25.38% |
2004 | -$14.77 | 51.08% |
2003 | -$9.78 | 4032.42% |
2002 | -$0.24 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
Regeneron Pharmaceuticals REGN | $37.36 | -7,149.06% | ๐บ๐ธ USA |
Pieris Pharmaceuticals PIRS | -$0.37 | -30.19% | ๐บ๐ธ USA |
Aeterna Zentaris AEZS | -$4.66 | 779.25% | ๐บ๐ธ USA |